Jinying Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jinying Lin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Danli Meng
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
5 shared publicationsRongjun Huang
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
5 shared publicationsYanting Yang
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
5 shared publicationsYijia Huang
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
5 shared publicationsRongxiu Huo
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
4 shared publicationsXiaocong Huo
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China
4 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (5) , 1-11
Role of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review)
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized primarily by arterial and/or venous thrombosis, obstetric complications and persistent positivity for antiphospholipid antibodies (aPLs). It has been proposed that the pathogenesis of APS is closely associated with vascular endothelial cell activation, complement activation and platelet activation. Notably, APS may be key to understanding the relationship between innate immune cells, and thrombosis and obstetric complications. Monocytes are activated by aPLs, adopting a pro‑inflammatory and pro‑coagulant phenotype, and producing inflammatory cytokines; however, the exact mechanisms of action of monocytes in APS remain unclear. Monocytes may act as an intermediary, triggering immune dysregulation, closely linking them to thrombosis and obstetric complications. Therefore, a better understanding of the potential pathogenic role of monocytes in APS is required, which could assist clinicians in gaining deeper insights into the pathogenesis of APS and identifying new therapeutic targets. This may provide new options for the management of APS. Therefore, the present study aimed to review monocytes and their role in APS.
- 2 September 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (5) , 1-11
Open AccessRole of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review)
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized primarily by arterial and/or venous thrombosis, obstetric complications and persistent positivity for antiphospholipid antibodies (aPLs). It has been proposed that the pathogenesis of APS is closely associated with vascular endothelial cell activation, complement activation and platelet activation. Notably, APS may be key to understanding the relationship between innate immune cells, and thrombosis and obstetric complications. Monocytes are activated by aPLs, adopting a pro‑inflammatory and pro‑coagulant phenotype, and producing inflammatory cytokines; however, the exact mechanisms of action of monocytes in APS remain unclear. Monocytes may act as an intermediary, triggering immune dysregulation, closely linking them to thrombosis and obstetric complications. Therefore, a better understanding of the potential pathogenic role of monocytes in APS is required, which could assist clinicians in gaining deeper insights into the pathogenesis of APS and identifying new therapeutic targets. This may provide new options for the management of APS. Therefore, the present study aimed to review monocytes and their role in APS.
- Open Access
- 21 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Analysis of related deaths in patients with systemic sclerosis combined with renal failure in the United States from 1999 to 2020
To describe the number of deaths related to systemic sclerosis (SSc) having renal failure, the changing trend in ASMR, and causes of death using a multi-cause method. Annual death toll and ASMR data from 1999 to 2020 were obtained from the death database of the US CDC. All death certificates in the M34 (SSc) and N17-19 (renal failure) categories of the ICD-10 were selected as potential or related causes of death. The epidemiology was described, and number of deaths and ASMR trends were analyzed. NCI-Joinpoint Analysis was used to test the changing trends in different years. For 22 years, 39,496 and 5,163 deaths were related to SSc and SSc having renal failure, respectively. There were 1,139 males (22.1%) with SSc having renal failure and 4,024 females (77.9%) with 1:3.5 male-to-female ratio. The number of female deaths and the ASMR were higher than those of male deaths, and decreased. Most deaths occurred approximately > 75 years. The number of deaths in different age groups showed a downward trend. Acute renal function was dominant in patients with SSc. Although the mortality rate of SSc having renal failure was relatively low and decreasing, timely diagnosis and treatment are required to reduce the mortality rate.
- 21 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessAnalysis of related deaths in patients with systemic sclerosis combined with renal failure in the United States from 1999 to 2020
To describe the number of deaths related to systemic sclerosis (SSc) having renal failure, the changing trend in ASMR, and causes of death using a multi-cause method. Annual death toll and ASMR data from 1999 to 2020 were obtained from the death database of the US CDC. All death certificates in the M34 (SSc) and N17-19 (renal failure) categories of the ICD-10 were selected as potential or related causes of death. The epidemiology was described, and number of deaths and ASMR trends were analyzed. NCI-Joinpoint Analysis was used to test the changing trends in different years. For 22 years, 39,496 and 5,163 deaths were related to SSc and SSc having renal failure, respectively. There were 1,139 males (22.1%) with SSc having renal failure and 4,024 females (77.9%) with 1:3.5 male-to-female ratio. The number of female deaths and the ASMR were higher than those of male deaths, and decreased. Most deaths occurred approximately > 75 years. The number of deaths in different age groups showed a downward trend. Acute renal function was dominant in patients with SSc. Although the mortality rate of SSc having renal failure was relatively low and decreasing, timely diagnosis and treatment are required to reduce the mortality rate.
- Open Access
- 23 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (21) , e42548
Mortality associated with systemic lupus erythematosus combined with heart failure in the United States (1999–2020): A multiple-cause-of-death study
This study analyzes the number of deaths related to systemic lupus erythematosus (SLE) combined with heart failure (HF) in the United States from 1999 to 2020, as well as the changing trend and causes of death of age-standardized mortality rate (ASMR). The annual number of deaths and ASMR with M32 (SLE) and I50 (HF) as the causes of death from 1999 to 2020 were extracted from the mortality database of the US CDC. Referring to the ICD-10 classification standard, the epidemiology and related data were described, and the number of deaths and the trend of ASMR were analyzed. A 2 trend test was conducted on the changing trend. Over the past 22 years, the total number of deaths related to SLE in the United States was 47,337, and the total number of deaths combined with HF was 3896, accounting for 8.2% of all deaths related to SLE. The number of male deaths from SLE combined with HF was 606 (15.6%), and that of female deaths was 3290 (84.4%), with a male-to-female ratio of approximately 1:5.4. The number of deaths related to SLE and SLE combined with HF showed an upward trend, and the difference in trend change was statistically significant (P < .001). Regarding ASMR, SLE shows a downward trend, while SLE combined with HF shows a slow upward trend. When it was regarded as MCD, both females and males showed an overall upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .673). The overall U/M shows a downward trend. The number of deaths in different age groups showed an upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .543). At present, chronic lower respiratory diseases are the leading cause of death, followed by malignant neoplasms. Although the number of deaths and ASMR in SLE combined with HF is relatively low, it shows a slow upward trend overall. Therefore, for patients with this disease, medical workers should be vigilant, provide timely diagnosis and treatment, and further reduce the mortality rate.
- 23 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (21) , e42548
Open AccessMortality associated with systemic lupus erythematosus combined with heart failure in the United States (1999–2020): A multiple-cause-of-death study
This study analyzes the number of deaths related to systemic lupus erythematosus (SLE) combined with heart failure (HF) in the United States from 1999 to 2020, as well as the changing trend and causes of death of age-standardized mortality rate (ASMR). The annual number of deaths and ASMR with M32 (SLE) and I50 (HF) as the causes of death from 1999 to 2020 were extracted from the mortality database of the US CDC. Referring to the ICD-10 classification standard, the epidemiology and related data were described, and the number of deaths and the trend of ASMR were analyzed. A 2 trend test was conducted on the changing trend. Over the past 22 years, the total number of deaths related to SLE in the United States was 47,337, and the total number of deaths combined with HF was 3896, accounting for 8.2% of all deaths related to SLE. The number of male deaths from SLE combined with HF was 606 (15.6%), and that of female deaths was 3290 (84.4%), with a male-to-female ratio of approximately 1:5.4. The number of deaths related to SLE and SLE combined with HF showed an upward trend, and the difference in trend change was statistically significant (P < .001). Regarding ASMR, SLE shows a downward trend, while SLE combined with HF shows a slow upward trend. When it was regarded as MCD, both females and males showed an overall upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .673). The overall U/M shows a downward trend. The number of deaths in different age groups showed an upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .543). At present, chronic lower respiratory diseases are the leading cause of death, followed by malignant neoplasms. Although the number of deaths and ASMR in SLE combined with HF is relatively low, it shows a slow upward trend overall. Therefore, for patients with this disease, medical workers should be vigilant, provide timely diagnosis and treatment, and further reduce the mortality rate.
- Open Access
- 16 September 2024
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 19 (1) , 568
Mortality associated with osteoporosis and pathological fractures in the United States (1999–2020): a multiple-cause-of-death study
Osteoporosis with pathological fractures is a significant public health issue, contributing to morbidity, disability, diminished quality of life, and increased mortality. Understanding mortality trends related to this condition is crucial for developing effective interventions to reduce mortality and improve healthcare outcomes. This study aimed to analyze trends and causes of death associated with osteoporosis and pathological fractures in the United States using a multi-cause approach. Annual death and age-standardized mortality rate (ASMR) data from 1999 to 2020 were obtained from the Centers for Disease Control and Prevention (CDC) mortality database. Death certificates listing ICD-10 M82 (osteoporosis with pathological fracture) as an underlying or related cause of death were analyzed. Epidemiological data were analyzed, and the ASMR data were calculated for each year, and trends were assessed using the Cochran-Armitage trend test. From 1999 to 2020, there were 40,441 deaths related to osteoporosis with pathological fractures in the United States, with a female-to-male ratio of 5.6:1. Among these, 12,820 deaths (31.7%) listed osteoporosis with pathological fractures as the underlying cause of death (UCD), yielding a female-to-male ASMR ratio of approximately 5.0-7.7:1. When classified as a non-UCD, the ASMR ratio was approximately 4.8-6.2:1. At the same time, we found that the total number of deaths classified as UCD and multiple causes of death (MCD), but the trend ratio of the two groups in different years did not change statistically significant (P > 0.05), and the ASMR of both groups showed a downward trend. The UCD-to-MCD ratio increased between 1999 and 2007, then decreased from 2007 to 2020. As MCD, the number of female deaths was more than that of male, and both showed a decreasing trend, but there was no statistical significance in the change of trend ratio in different years (P > 0.05). Deaths were predominantly concentrated in individuals over 75 years of age, with those over 84 years being the most affected. The number of deaths in different age groups showed a decreasing trend, and the change of trend ratio in different years was statistically significant (P < 0.05). White individuals had the highest number of deaths. The leading causes of death were heart diseases, chronic lower respiratory diseases, and alzheimer's disease. In addition, the number of deaths of patients with prostate cancer and breast cancer showed a significant downward trend, and the change of trend ratio between the two groups in different years was statistically significant (P < 0.05). Although mortality from osteoporosis with pathological fractures is decreasing, anti-osteoporosis therapy remains essential for elderly patients. Healthcare providers should remain vigilant for potential complications, including malignant neoplasms, and ensure timely diagnosis and treatment to further reduce mortality in this population.
- 16 September 2024
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 19 (1) , 568
Open AccessMortality associated with osteoporosis and pathological fractures in the United States (1999–2020): a multiple-cause-of-death study
Osteoporosis with pathological fractures is a significant public health issue, contributing to morbidity, disability, diminished quality of life, and increased mortality. Understanding mortality trends related to this condition is crucial for developing effective interventions to reduce mortality and improve healthcare outcomes. This study aimed to analyze trends and causes of death associated with osteoporosis and pathological fractures in the United States using a multi-cause approach. Annual death and age-standardized mortality rate (ASMR) data from 1999 to 2020 were obtained from the Centers for Disease Control and Prevention (CDC) mortality database. Death certificates listing ICD-10 M82 (osteoporosis with pathological fracture) as an underlying or related cause of death were analyzed. Epidemiological data were analyzed, and the ASMR data were calculated for each year, and trends were assessed using the Cochran-Armitage trend test. From 1999 to 2020, there were 40,441 deaths related to osteoporosis with pathological fractures in the United States, with a female-to-male ratio of 5.6:1. Among these, 12,820 deaths (31.7%) listed osteoporosis with pathological fractures as the underlying cause of death (UCD), yielding a female-to-male ASMR ratio of approximately 5.0-7.7:1. When classified as a non-UCD, the ASMR ratio was approximately 4.8-6.2:1. At the same time, we found that the total number of deaths classified as UCD and multiple causes of death (MCD), but the trend ratio of the two groups in different years did not change statistically significant (P > 0.05), and the ASMR of both groups showed a downward trend. The UCD-to-MCD ratio increased between 1999 and 2007, then decreased from 2007 to 2020. As MCD, the number of female deaths was more than that of male, and both showed a decreasing trend, but there was no statistical significance in the change of trend ratio in different years (P > 0.05). Deaths were predominantly concentrated in individuals over 75 years of age, with those over 84 years being the most affected. The number of deaths in different age groups showed a decreasing trend, and the change of trend ratio in different years was statistically significant (P < 0.05). White individuals had the highest number of deaths. The leading causes of death were heart diseases, chronic lower respiratory diseases, and alzheimer's disease. In addition, the number of deaths of patients with prostate cancer and breast cancer showed a significant downward trend, and the change of trend ratio between the two groups in different years was statistically significant (P < 0.05). Although mortality from osteoporosis with pathological fractures is decreasing, anti-osteoporosis therapy remains essential for elderly patients. Healthcare providers should remain vigilant for potential complications, including malignant neoplasms, and ensure timely diagnosis and treatment to further reduce mortality in this population.
- Open Access
- 14 August 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 30 (4) , 1-12
Potential of resveratrol in the treatment of systemic lupus erythematosus (Review)
Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions. Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.
- 14 August 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 30 (4) , 1-12
Open AccessPotential of resveratrol in the treatment of systemic lupus erythematosus (Review)
Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions. Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.